Mary Carrington Selected Research

tapasin

11/2023	Mass Spectrometric Profiling of HLA-B44 Peptidomes Provides Evidence for Tapasin-Mediated Tryptophan Editing.
1/2022	Genetic variation that determines TAPBP expression levels associates with the course of malaria in an HLA allotype-dependent manner.
11/2020	HLA tapasin independence: broader peptide repertoire and HIV control.
6/2014	Distinct assembly profiles of HLA-B molecules.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary Carrington Research Topics

Disease

67	Infections 04/2024 - 05/2002
23	Acquired Immunodeficiency Syndrome (AIDS) 01/2024 - 01/2002
23	Viremia 12/2023 - 09/2006
21	Neoplasms (Cancer) 01/2024 - 04/2002
20	Disease Progression 01/2019 - 10/2006
18	HIV Infections (HIV Infection) 05/2024 - 05/2006
9	Virus Diseases (Viral Diseases) 01/2017 - 08/2002
6	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020 - 06/2007
5	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2024 - 11/2007
4	COVID-19 01/2022 - 01/2021
4	Communicable Diseases (Infectious Diseases) 12/2021 - 01/2003
3	Disease Susceptibility (Diathesis) 01/2023 - 04/2015
3	Nasopharyngeal Carcinoma 01/2012 - 11/2005
3	Myositis (Idiopathic Inflammatory Myopathies) 11/2006 - 11/2005
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2024 - 01/2021
2	Liver Diseases (Liver Disease) 10/2023 - 06/2011
2	Inflammation (Inflammations) 10/2023 - 10/2020
2	Urinary Bladder Neoplasms (Bladder Cancer) 12/2022 - 01/2022
2	Hepatitis C 01/2022 - 06/2009
2	Malaria 01/2022 - 12/2017
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020 - 02/2012
2	Kaposi Sarcoma (Kaposi's Sarcoma) 11/2019 - 02/2016
2	Persistent Infection 01/2018 - 06/2012
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 06/2010
2	Hypersensitivity (Allergy) 01/2017 - 03/2011
2	Crohn Disease (Crohn's Disease) 12/2013 - 04/2013
2	Chronic Hepatitis B 06/2012 - 11/2003
2	Hepatitis B 06/2012 - 12/2008
2	Polymyositis 11/2006 - 11/2005
2	Dermatomyositis (Dermatopolymyositis) 11/2006 - 11/2005
2	Psoriatic Arthritis 10/2004 - 09/2002
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2024
1	Sclerosing Cholangitis 10/2023
1	Pathologic Constriction (Stenosis) 10/2023
1	Ulcerative Colitis 10/2023
1	Glioma (Gliomas) 01/2023
1	Rhabdomyosarcoma 01/2023
1	Lung Neoplasms (Lung Cancer) 01/2023
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2023
1	Osteosarcoma (Osteogenic Sarcoma) 01/2023

Drug/Important Bio-Agent (IBA)

29	HLA-B Antigens (HLA-B)IBA 05/2024 - 08/2002
28	HLA Antigens (Human Leukocyte Antigens)IBA 01/2024 - 04/2002
22	LigandsIBA 04/2024 - 05/2002
18	EpitopesIBA 01/2024 - 10/2006
18	Peptides (Polypeptides)IBA 11/2023 - 11/2005
16	HLA-C Antigens (HLA-C)IBA 01/2021 - 09/2002
14	Proteins (Proteins, Gene)FDA Link 02/2023 - 01/2003
12	RNA (Ribonucleic Acid)IBA 01/2024 - 06/2007
11	Antiviral Agents (Antivirals)IBA 04/2024 - 09/2002
11	VaccinesIBA 01/2022 - 05/2008
10	HLA-A Antigens (HLA-A)IBA 01/2024 - 10/2004
10	KIR ReceptorsIBA 01/2021 - 04/2005
7	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 01/2014
7	AntigensIBA 01/2023 - 05/2006
6	Natural Killer Cell ReceptorsIBA 10/2023 - 08/2004
6	InterferonsIBA 01/2022 - 09/2006
6	Immunoglobulins (Immunoglobulin)IBA 02/2016 - 05/2002
4	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 11/2023 - 10/2006
4	tapasinIBA 11/2023 - 06/2014
4	HLA-DP Antigens (HLA-DP)IBA 10/2023 - 06/2012
4	Messenger RNA (mRNA)IBA 01/2022 - 07/2010
4	CytokinesIBA 01/2022 - 08/2002
4	HLA-B57 antigenIBA 01/2018 - 02/2011
3	Histocompatibility Antigens Class IIBA 01/2023 - 03/2007
3	Amino Acids FDA Link 01/2022 - 12/2010
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2004
3	HLA-DPB1 antigen (HLA DPB1)IBA 01/2020 - 06/2012
3	Interferon-gamma (Interferon, gamma)IBA 11/2014 - 06/2012
3	HLA-DRB1 Chains (HLA DRB1)IBA 07/2013 - 03/2006
3	ChemokinesIBA 11/2010 - 05/2009
3	Chemokine ReceptorsIBA 01/2007 - 01/2002
2	Histocompatibility Antigens Class IIIBA 01/2023 - 01/2008
2	transporter associated with antigen processing (TAP)IBA 01/2023 - 05/2003
2	HLA-DR Antigens (HLA-DR)IBA 01/2023 - 01/2002
2	Broadly Neutralizing AntibodiesIBA 12/2019 - 12/2015
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017 - 06/2012
2	MicroRNAs (MicroRNA)IBA 12/2016 - 01/2014
2	EnzymesIBA 11/2014 - 11/2014
2	Codon (Codons)IBA 08/2014 - 08/2009
2	3' Untranslated Regions (3' UTR)IBA 12/2013 - 06/2012
2	HLA-DRB1*03:01 antigenIBA 07/2013 - 11/2006
2	HLA-Bw4 antigenIBA 06/2011 - 08/2007
2	Antigen Receptors (Antigen Receptor)IBA 05/2009 - 05/2009
2	DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA 11/2007 - 12/2004
2	C-Type Lectins (C-Type Lectin)IBA 11/2007 - 12/2004
2	Isoleucine (L-Isoleucine)FDA Link 08/2007 - 08/2002
2	AutoantibodiesIBA 11/2006 - 03/2006
1	HLA-DPA1 antigen (HLA DPA1)IBA 10/2023
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2023
1	Interleukin-13IBA 01/2023
1	Interleukin-5 (Interleukin 5)IBA 01/2023

Therapy/Procedure

15	Therapeutics 01/2024 - 10/2007
5	Transplantation 01/2022 - 12/2014
3	Immunotherapy 01/2024 - 12/2022
3	Art Therapy 12/2023 - 09/2014
3	Highly Active Antiretroviral Therapy (HAART) 03/2023 - 09/2006
3	Cell Transplantation 01/2020 - 01/2020
2	Precision Medicine 01/2023 - 12/2021
2	Aftercare (After-Treatment) 02/2022 - 01/2022
1	Liver Transplantation 10/2023